passiv
transfer
matern
immun
respons
keep
mammalian
speci
aliv
process
evolut
develop
effect
mechan
passiv
transfer
system
mucos
immun
mother
offspr
experiment
passiv
transfer
system
immun
via
serum
antibodi
well
establish
experiment
passiv
transfer
mucos
immun
recent
accomplish
chapter
address
contribut
natur
experiment
mechan
studi
passiv
immun
transfer
system
immun
igg
mother
offspr
occur
prenat
via
placenta
yolk
sac
birth
via
colostrum
speci
vari
contribut
rout
make
transfer
immun
waldman
strober
group
three
categori
prenat
transfer
combin
prenat
postnat
transfer
postnat
transfer
group
includ
primat
rabbit
guinea
pig
transport
igg
primat
occur
almost
exclus
placenta
igg
transfer
occur
via
receptormedi
transcytosi
across
syncytiotrophoblast
transcellular
pathway
fetal
endothelium
leach
et
al
human
placent
transfer
protect
igg
antibodi
number
pathogen
includ
hepat
b
hockel
kaufman
measl
lennon
black
group
b
streptococcu
baker
et
al
report
process
suggest
effect
method
neonat
immun
ie
immun
pregnant
mother
order
protect
neonat
prenat
transfer
igg
rabbit
occur
via
yolk
sac
guinea
pig
via
yolk
sac
fetal
gut
waldman
strober
group
includ
rat
mice
cat
dog
prenat
transmiss
occur
via
yolk
sacplacenta
fetal
gut
rat
waldman
strober
igg
bound
rapidli
receptor
surfac
yolk
sac
membran
mucchielli
et
al
endocytos
clathrinco
vesicl
earli
gestat
store
subap
vacuol
late
gestat
antibodi
hydrolyz
transfer
fetal
capillari
jolli
prenat
transmiss
mice
occur
similar
mechan
gardner
although
placent
transfer
occur
studi
rodent
shown
transport
antibodi
occur
postnat
colostrum
milk
arangojaramillo
et
al
barthold
et
al
heiman
weisman
kohl
loo
nejamki
et
al
oda
et
al
period
day
depend
speci
gradual
decreas
transmiss
last
day
waldman
strober
transmiss
limit
antibodi
igg
class
applebi
catti
hammerberg
et
al
transport
receptormedi
process
simist
ree
rat
receptor
fcrn
found
enterocyt
proxim
intestin
earli
postnat
period
absent
wean
jakoi
et
al
fcrn
specif
igg
fc
fragment
consist
two
similar
polypeptid
dalton
associ
microglobulin
jakoi
et
al
simist
mostov
fc
bind
subunit
three
extracellular
domain
transmembran
region
homolog
correspond
domain
class
major
histocompat
complex
mhc
antigen
simist
mostov
junghan
anderson
shown
disrupt
fcrn
knockout
mice
also
destroy
receptor
fcrp
necessari
prolong
halflif
serum
igg
adult
suggest
receptor
protein
mediat
transient
igg
transport
across
neonat
gut
function
fcrp
throughout
life
group
includ
rumin
cattl
sheep
goat
hors
pig
review
tizzard
transport
colostr
protein
lumen
ileum
rumin
larg
nonspecif
hors
pig
igg
igm
preferenti
absorb
protein
activ
taken
epitheli
cell
pinocytosi
pass
cell
lacteal
intestin
capillari
tizzard
intestin
absorpt
occur
first
hour
birth
follow
open
gut
close
transfer
milk
colostrum
occur
elli
et
al
franci
black
tizzard
waldman
strober
newborn
piglet
also
shown
absorb
colostr
lymphoid
cell
period
tuboli
et
al
unclear
whether
cell
fulli
function
capabl
immun
process
transfer
delayedtyp
hypersensit
dth
absorpt
colostr
immunoglobulin
normal
extrem
effect
suppli
newborn
serum
immunoglobulin
particularli
igg
level
approach
found
adult
tizzard
howev
failur
passiv
transfer
fpt
occur
pose
consider
problem
anim
husbandri
newborn
foal
fail
obtain
suffici
quantiti
immunoglobulin
mcguir
et
al
tizzard
mcguir
studi
two
nine
foal
affect
fpt
die
infect
within
day
birth
five
remain
seven
develop
nonfat
respiratori
infect
week
age
mcguir
et
al
also
report
fpt
calv
find
calv
less
week
old
die
infecti
diseas
signific
hypogammaglobulinemia
although
adequ
method
diagnos
treat
fpt
avail
berton
et
al
tizzard
phenomenon
remain
signific
veterinari
problem
mother
milk
provid
passiv
protect
mucos
surfac
contact
protect
may
mediat
either
specif
immun
nonspecif
factor
found
milk
lactoferrin
lysozym
fatti
acid
complement
review
goldman
et
al
antibodi
composit
milk
differ
colostrum
tizzard
class
protect
antibodi
milk
vari
speci
rout
immun
mother
except
igg
rodent
protect
antibodi
system
absorb
suckl
offspr
exert
protect
effect
local
neutral
virus
virul
factor
bind
microbi
pathogen
prevent
attach
mucos
surfac
goldman
et
al
secretori
iga
siga
especi
suit
protect
role
secretori
compon
enhanc
resist
proteolyt
enzym
gastric
acid
kenni
et
al
lindh
tomasi
zikan
et
al
provid
extra
antibodi
stabil
mucos
secret
rodent
popular
model
studi
passiv
transfer
matern
immun
via
milk
howev
class
anim
major
drawback
model
passiv
mucos
immun
rat
mice
activ
transport
igg
gut
serum
approxim
week
see
combin
prenat
postnat
transfer
earlier
chapter
thu
observ
protect
could
due
either
antibodi
milk
bath
mucos
surfac
matern
antibodi
transport
serum
secret
offspr
caveat
kept
mind
evalu
mani
report
milkborn
protect
speci
three
rodent
model
protect
mucos
surfac
due
milkborn
serumderiv
antibodi
describ
next
predomin
immunoglobulin
mous
milk
igg
although
signific
level
iga
also
present
ijaz
et
al
protect
infant
mice
colon
campylobact
jejuni
achiev
consumpt
immun
milk
time
bacteri
challeng
infant
mice
protect
prior
consumpt
colostrum
show
milk
antibodi
requir
gut
lumen
protect
observ
abmiku
dolbi
similar
requir
antibodi
activ
intestin
cell
surfac
immun
primat
rotaviru
report
offit
clark
protect
rat
dental
cari
milk
due
either
igg
siga
antibodi
depend
rout
matern
immun
rat
dam
immun
intraven
heatkil
streptococcu
mutan
develop
igg
antibodi
colostrum
milk
serum
offspr
demonstr
signific
protect
mutansinduc
cari
format
rat
dam
local
inject
region
mammari
gland
heatkil
mutan
fed
formalinkil
mutan
develop
siga
antibodi
colostrum
milktheir
offspr
also
protect
cari
format
michalek
mcghee
cari
protect
suckl
rat
could
theoret
due
bath
mucos
surfac
andor
leakag
antibodi
saliva
serum
nonimmun
adult
rat
protect
mutansinduc
cari
feed
lyophil
immun
bovin
milk
immun
bovin
whey
contain
specif
igg
michalek
et
al
michalek
et
al
sinc
adult
rat
unabl
transport
oral
administ
igg
serum
protect
must
milkderiv
antibodi
bath
oral
caviti
rumin
sheep
cattl
goat
predomin
antibodi
colostrum
milk
igg
predomin
antibodi
colostrum
pig
hors
also
igg
lactat
progress
colostrum
becom
milk
iga
predomin
tizzard
protect
mediat
either
antibodi
class
bath
mucos
surfac
milkderiv
antibodi
provid
passiv
immun
pathogen
high
rate
infect
fpt
foal
calv
show
milk
mucos
immun
alon
provid
complet
protect
neonat
cattl
pig
passiv
immun
enter
infect
virus
rotavirus
coronavirus
transmiss
gastroenter
tge
depend
continu
presenc
gut
lumen
protect
level
specif
antibodi
crouch
passiv
immun
intestin
infect
tge
viru
gener
complet
piglet
ingest
iga
antibodi
ingest
igg
antibodi
although
class
antibodi
protect
class
antibodi
present
sow
milk
depend
rout
immun
bohl
saif
cattl
passiv
immun
calf
scour
neonat
bovin
colibacillosi
caus
escherichia
coli
correl
level
specif
iga
antibodi
mother
milk
wilson
jutila
primat
iga
predomin
immunoglobulin
colostrum
milk
tizzard
lysozym
siga
human
milk
remain
function
digest
tract
earli
infant
eschenburg
et
al
human
milk
shown
contain
siga
antibodi
least
five
viral
nine
bacteri
pathogen
well
fungi
parasit
food
antigen
goldman
et
al
mucos
immun
rotaviru
exampl
shown
transfer
infant
siga
milk
posit
correl
titer
secretori
compon
sc
mother
milk
infant
fece
vs
virusspecif
iga
infant
fecal
sampl
rahman
et
al
addit
provid
passiv
mucos
immun
human
breast
milk
also
stimul
earli
local
product
siga
urinari
gastrointestin
tract
therebi
acceler
develop
activ
local
host
defens
infant
koutra
vigorita
prentic
sinc
origin
demonstr
transfer
immun
inject
serum
von
behr
kitasato
passiv
transfer
humor
immun
intens
investig
use
specif
serum
antibodi
igg
transfer
protect
nonimmun
individu
standard
medic
practic
exampl
postexposur
prophylaxi
rabi
tetanu
treatment
snakebit
arnold
center
diseas
control
intraven
immunoglobulin
ivig
treatment
shown
lower
incid
pneumonia
patient
common
variabl
immunodefici
buss
et
al
local
immun
correl
level
iga
antibodi
variou
secret
review
renegar
small
howev
direct
demonstr
mediat
local
immun
inject
iga
could
occur
specif
transport
passiv
administ
iga
confirm
rabbit
rat
mice
polymer
iga
piga
effici
transport
circul
bile
via
liver
delacroix
et
al
koertg
butler
mestecki
mcghee
orlan
et
al
orlan
et
al
speci
express
pig
receptor
pigr
hepatocyt
socken
et
al
addit
piga
primari
molecular
form
serum
hereman
vaerman
serum
iga
also
effici
transport
bile
cattl
butler
et
al
fact
iga
rumin
bile
may
serum
origin
transport
serum
iga
bile
human
report
delacroix
et
al
dooley
et
al
although
iga
transport
less
effici
rat
rabbit
human
biliari
iga
level
approxim
human
serum
iga
level
physiolog
condit
human
biliari
iga
deriv
serum
vaerman
delacroix
even
though
transport
possibl
passiv
administ
iga
reach
high
level
human
bile
one
studi
less
intraven
inject
radiolabel
piga
found
human
bile
hour
vaerman
delacroix
serum
piga
transport
saliva
dog
montgomeri
et
al
monkey
challacomb
et
al
mice
falerodiaz
et
al
human
delacroix
et
al
kubagawa
et
al
human
amount
iga
acquir
plasma
low
compar
amount
acquir
local
product
delacroix
et
al
transfer
piga
plasma
canin
murin
saliva
select
process
requir
pigr
montgomeri
et
al
falerodiaz
et
al
transport
oral
fluid
monkey
appear
leakag
plasma
crevicular
space
surround
decidu
molar
challacomb
et
al
sheep
activ
transport
iga
circul
milk
seem
like
sheldrak
et
al
howev
studi
transport
iga
murin
milk
produc
conflict
result
use
radiolabel
iga
halsey
et
al
demonstr
mous
iga
transport
circul
milk
earli
lactat
investig
koertg
butler
russel
et
al
use
assay
base
antibodybind
activ
unabl
show
transport
iga
murin
milk
use
radiolabel
iga
koertg
butler
abl
show
iga
present
milk
degrad
suggest
previou
studi
halsey
et
al
detect
iga
fragment
transud
milk
serum
specif
transport
iga
passiv
administ
iga
transport
milk
rat
dahlgren
et
al
koertg
butler
limit
number
studi
transport
antibodi
respiratori
secret
report
result
shown
select
transport
passiv
administ
serum
iga
respiratori
tract
possibl
sheep
mice
import
background
experi
demonstr
passiv
transfer
local
immun
iga
respiratori
transport
studi
address
detail
sheep
use
intraven
inject
radioiodin
ovin
immunoglobulin
scicchitano
et
al
show
iga
mediastin
lymph
sheep
plasmaderiv
demonstr
scicchitano
et
al
simultan
intraven
inject
radiolabel
iga
radiolabel
igg
igg
iga
select
transport
ovin
respiratori
secret
transport
iga
approxim
time
greater
transport
igg
transport
iga
intact
secret
biolog
activ
transport
iga
determin
mice
mazanec
et
al
found
hour
intraven
inject
radiolabel
monomer
polymer
iga
antisendai
viru
monoclon
antibodi
mice
transport
piga
nasal
secret
three
seven
time
effici
transport
monomer
iga
miga
piga
transport
bronchoalveolar
lavag
one
three
time
effici
differ
may
reflect
increas
contribut
serum
antibodi
due
transud
igg
alveolar
fluid
transport
piga
gut
four
five
time
effici
transport
miga
expect
agreement
nasal
secret
gut
transport
indic
suggest
transport
two
site
could
occur
similar
mechan
investig
unabl
demonstr
presenc
function
intact
piga
upper
respiratori
tract
piga
transport
murin
nasal
secret
studi
report
renegar
small
contrast
function
intact
avoid
problem
associ
quantif
intact
vs
degrad
radiolabel
iga
secret
describ
koertg
butler
studi
use
antiinfluenza
enzymelink
immunosorb
assay
elisa
evalu
transport
monomer
polymer
iga
igg
monoclon
antiinfluenza
antibodi
nasal
secret
mice
nonimmun
mice
inject
intraven
influenzaspecif
miga
piga
igg
sacrif
vari
time
hour
postinject
peak
nasal
wash
piga
titer
reach
hour
antibodi
inject
approxim
time
greater
nasal
wash
titer
either
monomer
immunoglobulin
determin
whether
piga
select
transport
rel
igg
investig
inject
mixtur
two
monoclon
intraven
nonimmun
mice
calcul
select
transport
index
nasal
antibodi
mous
twentynin
mice
studi
show
select
transport
iga
rel
igg
use
similar
model
steinmetz
et
al
determin
passiv
administ
monoclon
piga
isotypeswitch
variant
gener
igg
hybridoma
produc
antibodi
specif
bacteri
respiratori
tract
pathogen
select
transport
rel
igg
upper
lower
respiratori
tract
secret
mice
agreement
result
renegar
small
falerodiaz
et
al
show
mice
parenter
administ
either
intraven
backpack
tumor
growth
monoclon
piga
acquir
sc
transport
serum
nasal
vagin
secret
bile
similarli
administ
igg
suggest
specif
transport
iga
igg
contrast
steinmetz
et
al
agreement
mazanec
et
al
falerodiaz
group
found
effici
transmiss
igg
piga
lung
mice
fact
found
topic
administr
light
anesthesia
iga
nosedrop
effect
method
deliveri
iga
lung
either
parenter
method
thu
transport
serum
iga
nasal
secret
possibl
speci
relev
transport
passiv
transfer
local
immun
address
follow
section
studi
passiv
transfer
local
immun
classifi
two
categori
first
studi
antibodi
introduc
local
secret
exogen
mix
target
pathogen
prior
host
challeng
second
categori
includ
studi
system
administ
piga
must
physiolog
transport
pigrmedi
mechan
site
activ
studi
categori
investig
role
iga
mucos
immun
feed
antibodi
instil
intranas
intravagin
challeng
administ
antibodypathogen
mixtur
intranas
oral
antibodi
offit
clark
demonstr
abil
milkderiv
igg
iga
protect
murin
intestin
infect
primat
rotaviru
suckl
mice
protect
milk
dam
oral
immun
viru
protect
activ
detect
igg
iga
fraction
iga
fraction
potent
vivo
igg
fraction
newborn
mice
immun
dam
fosternurs
seroneg
dam
presenc
circul
system
antirotaviru
antibodi
high
titer
protect
viral
infect
thu
specif
antibodi
present
gut
lumen
protect
intestin
cell
surfac
viral
infect
siga
could
mediat
protect
enriquez
rigg
develop
seri
dimer
iga
monoclon
antibodi
direct
toward
sporozoit
antigen
cryptosporidium
parvum
import
diarrheacaus
protozoan
parasit
administ
oral
prior
parasit
challeng
antibodi
abl
reduc
number
intestin
parasit
infect
neonat
mice
result
extend
work
albert
et
al
success
treat
cryptosporidiosi
nude
mice
oral
administr
rat
bile
contain
c
parvumspecif
iga
czinn
et
al
protect
germfre
mice
infect
helicobact
feli
incub
bacteria
specif
iga
antibodi
prior
oral
administr
protect
antibodi
later
shown
direct
ureas
blanchard
et
al
signific
number
system
infect
human
neonat
origin
gastrointestin
tract
especi
prematur
infant
immatur
gut
barrier
maxson
et
al
fed
rabbit
pup
human
siga
via
intragastr
gavag
challeng
e
coli
igatr
pup
significantli
fewer
bacteria
transloc
gut
liver
spleen
mesenter
lymph
node
neonat
rabbit
model
provid
first
demonstr
control
bacteri
transloc
iga
suggest
oral
supplement
iga
may
benefici
patient
risk
gutorigin
sepsi
intranas
antibodi
number
studi
shown
exogen
administ
iga
protect
intranas
challeng
pathogen
bessen
fischetti
show
siga
given
intranas
rout
protect
mice
streptococc
infect
live
streptococci
mix
affinitypurifi
human
salivari
siga
serum
igg
antibodi
direct
toward
streptococc
protein
mixtur
administ
intranas
mice
siga
antibodi
protect
streptococc
infect
serum
antibodi
effect
studi
suggest
siga
alon
capabl
protect
mucosa
bacteri
invas
demonstr
iga
protect
mucos
surfac
viral
infect
ascit
contain
iga
antisendai
viru
monoclon
antibodi
administ
intranas
lightli
anesthet
mice
mice
challeng
intranas
live
viru
three
day
later
mice
sacrif
lung
viral
titer
determin
anim
treat
specif
monoclon
antibodi
protect
viral
infect
work
laboratori
show
local
immun
sendai
viru
also
mediat
intranas
administ
igg
mazanec
et
al
tamura
et
al
purifi
antiinfluenza
siga
antibodi
respiratori
tract
mice
immun
influenza
hemagglutinin
molecul
iga
given
intranas
protect
nonimmun
mice
influenza
infect
protect
observ
day
antibodi
administr
proport
amount
iga
administ
observ
iga
dose
equival
natur
occur
antibodi
titer
intravagin
antibodi
zeitlin
et
al
abl
protect
mous
vagina
infect
herp
simplex
viru
topic
administr
either
igg
iga
monoclon
antibodi
direct
glycoprotein
studi
show
topic
administ
local
iga
igg
protect
viral
bacteri
infect
mucosa
show
physiolog
transport
secretori
iga
serumderiv
igg
actual
demonstr
antibodi
must
administ
parenter
transport
mucos
secret
physiolog
mechan
studi
present
next
section
satisfi
criterion
definit
studi
categori
involv
respiratori
gastrointestin
tract
although
passiv
transfer
uterin
immun
piga
also
observ
renegar
small
cotter
et
al
pal
et
al
leher
et
al
demonstr
protect
chines
hamster
pig
acanthamoeba
castellaniimedi
kerat
intraperiton
administ
antigenspecif
monoclon
iga
work
respiratori
gastrointestin
tract
present
detail
respiratori
tract
respiratori
tract
separ
upper
region
nose
trachea
lower
region
lung
bronchi
immun
site
involv
differ
element
immun
system
numer
studi
shown
passiv
administ
serum
antiinfluenza
antibodi
igg
prevent
lethal
viral
pneumonia
barber
small
kri
et
al
loosli
et
al
ramphal
et
al
palladino
et
al
serum
antibodi
howev
prevent
influenza
infect
upper
respiratori
tract
barber
small
kri
et
al
ramphal
et
al
protect
nose
correl
increas
nasal
secret
iga
antibodi
level
review
renegar
small
make
influenza
excel
model
investig
hypothesi
nasal
immun
mediat
siga
first
demonstr
passiv
transfer
local
immun
physiolog
transport
siga
report
renegar
small
murin
influenza
model
show
describ
intraven
administ
piga
transport
nasal
secret
determin
whether
intraven
administ
piga
antiinfluenza
monoclon
antibodi
could
mediat
protect
local
influenza
viru
challeng
passiv
immun
mice
challeng
intranas
awak
influenza
viru
twentyfour
hour
later
mice
sacrif
amount
viru
shed
nasal
secret
determin
salineinject
control
mice
shed
viru
nasal
secret
piga
inject
mice
shed
viru
shed
viru
low
titer
observ
protect
signific
p
passiv
immun
influenzaspecif
piga
therefor
confer
complet
protect
viral
infect
mice
partial
protect
remain
serum
igg
found
confer
limit
protect
nasal
influenza
infect
minim
reduct
viral
shed
p
one
eight
mice
intraven
inject
influenzaspecif
igg
shed
viru
p
passiv
protect
studi
show
iga
mediat
local
immun
confirm
iga
mediat
local
immun
mice
passiv
immun
piga
given
nose
drop
antiiga
antibodi
minut
hour
challeng
intranas
influenza
viru
suspend
antiiga
antiserum
antiiga
treatment
abrog
igamedi
protect
passiv
immun
mice
renegar
small
show
passiv
transfer
local
immun
iga
reflect
natur
situat
abrog
techniqu
extend
mice
convalesc
influenza
infect
renegar
small
nonimmun
mice
convalesc
mice
ie
mice
recov
influenza
viru
infect
week
earlier
therefor
natur
immun
treat
intranas
antiserum
iga
igg
mixtur
antisera
igg
igm
challeng
awak
influenza
viru
mix
antiserum
intranas
administr
antiserum
continu
interv
hour
one
day
viral
challeng
mice
kill
nasal
wash
assay
viru
shed
nonimmun
mice
becam
infect
regardless
whether
viru
administ
salin
normal
rabbit
serum
antiimmunoglobulin
antiserum
convalesc
mice
expect
protect
viral
infect
administr
influenza
viru
either
antiigg
mixtur
antiigg
antiigm
antisera
affect
protect
ie
convalesc
mice
still
immun
administr
viru
antiiga
antiserum
howev
abrog
convalesc
immun
result
demonstr
iga
major
mediat
murin
nasal
immun
suggest
passiv
immun
mimic
role
siga
play
natur
immun
observ
extend
work
philipon
et
al
use
backpack
method
monoclon
antibodi
administr
demonstr
monoclon
iga
antibodi
direct
shigella
flexneri
serotyp
lipopolysaccharid
protect
mice
intranas
challeng
flexneri
mbawuick
et
al
howev
use
iga
knockout
mous
model
challeng
find
mice
unabl
produc
iga
antibodi
abl
gener
protect
antiinfluenza
respons
transport
passiv
administ
antiinfluenza
antibodi
upper
lower
respiratori
tract
knockout
mice
howev
may
best
model
studi
role
iga
nasal
immun
congenit
loss
iga
product
class
antibodi
igg
may
increas
compensatori
mechan
data
mbawuick
et
al
suggest
may
case
influenzaspecif
igg
level
higher
immun
knockout
mice
normal
mice
alter
igg
subclass
distribut
respons
influenza
infect
observ
zhang
et
al
furthermor
perturb
mucos
iga
transport
pigr
knockout
mous
johansen
et
al
led
increas
mucos
leaki
increas
serum
total
igg
level
indic
defect
mucos
barrier
known
renegar
et
al
dose
high
enough
give
serum
titer
seven
time
normal
antiinfluenza
igg
titer
convalesc
mice
intraven
administ
influenzaspecif
igg
lower
elimin
nasal
secret
viral
load
howev
scan
electron
microscopi
reveal
even
high
igg
dose
prevent
infect
nasal
epithelium
thu
lower
nasal
secret
viral
titer
report
iggprotect
mice
may
due
neutral
newli
replic
viru
serum
antibodi
leak
viral
damag
epithelium
furthermor
serum
antiinfluenza
igg
antibodi
titer
sever
time
higher
normal
observ
igg
effect
observ
serum
antibodi
level
compar
normal
convalesc
mice
neither
depress
viral
shed
prevent
viral
patholog
nasal
epithelium
sinc
public
iga
knockout
mous
work
model
report
mucos
iga
level
depress
genet
normal
mice
serum
igg
remain
unaffect
renegar
et
al
renegar
et
al
mice
total
parenter
nutrit
tpn
depress
nasal
mucos
immun
influenza
viru
result
increas
viral
shed
nose
tpnfed
immun
mice
fig
mice
nasal
influenzaspecif
iga
sever
depress
fig
serum
antiinfluenza
igg
titer
unaffect
fig
thu
genet
normal
icr
mice
serum
igg
alon
capabl
prevent
viral
infect
nose
protect
could
restor
intraven
administr
influenzaspecif
piga
monoclon
antibodi
fig
work
strongli
suggest
iga
requir
prevent
influenza
viru
infect
nose
normal
mice
gastrointestin
tract
addit
evid
siga
mediat
local
immun
come
studi
gastrointestin
tract
polymer
iga
hybridoma
vibrio
cholera
gener
result
monoclon
antibodi
use
determin
whether
iga
mediat
immun
toward
bacteri
pathogen
gut
winner
et
al
investig
select
clone
produc
dimer
monoclon
iga
antibodi
direct
ogawaspecif
lipopolysaccarid
carbohydr
antigen
expos
bacteri
surfac
antibodi
abl
crosslink
bacteri
organ
vitro
suggest
might
effect
prevent
mucos
colon
pathogen
vivo
provid
continu
physiolog
ie
secretorycomponentmedi
transport
specif
antibodi
gut
hybridoma
cell
inject
subcutan
back
adult
balbc
mice
backpack
tumor
releas
monoclon
iga
circul
plasma
iga
transport
gut
lumen
neonat
mice
bear
backpack
tumor
surviv
challeng
v
cholera
neonat
mice
bear
backpack
tumor
unrel
iga
hybridoma
nontumorbear
neonat
mice
die
ingeni
model
provid
first
evid
siga
alon
mediat
mucos
immun
bacteri
pathogen
michetti
et
al
sinc
demonstr
pathogenspecif
monoclon
siga
protect
mice
infect
salmonella
typhimurium
follow
oral
challeng
backpack
model
also
use
treat
rotaviru
infect
gastrointestin
tract
mice
burn
et
al
nonneutr
monoclon
iga
antibodi
direct
major
inner
capsid
viral
protein
capabl
prevent
primari
resolv
chronic
murin
rotaviru
infect
find
consist
hypothesi
vivo
intracellular
viral
inactiv
piga
transcytosi
mechan
host
defens
rotaviru
infect
gener
approach
passiv
parenter
transfer
mucos
immun
proven
use
research
tool
determin
role
siga
protect
variou
mucos
pathogen
possibl
therapi
passiv
administ
iga
antibodi
problemat
passiv
protect
inject
highli
specul
question
effici
transport
target
mucos
surfac
potenti
advers
effect
intraven
iga
antibodi
serum
iga
associ
decreas
complement
activ
russel
et
al
decreas
immun
lysi
griffiss
goroff
systemat
administ
piga
may
also
suppress
specif
humor
cellular
respons
renger
small
unpublish
observ
thorough
knowledg
role
iga
play
regul
immun
respons
need
intraven
passiv
mucos
immun
becom
accept
mean
therapi
man
howev
direct
oral
respiratori
applic
antibodi
mucos
surfac
practic
accept
control
dental
carri
feasibl
target
topic
iga
administr
one
studi
particularli
intrigu
et
al
gener
monoclon
secretori
antibodi
transgen
plant
show
surviv
day
human
oral
caviti
furthermor
antibodi
afford
specif
protect
oral
streptococc
colon
least
month
literatur
contain
number
report
passiv
transfer
immun
gastrointestin
pathogen
human
review
bogstedt
et
al
et
al
immun
provid
oral
administr
purifi
human
igg
serum
iga
use
prophylact
therapeut
measur
rotaviru
infect
children
barn
et
al
guarino
et
al
therapeut
measur
bacteri
diarrhea
tjellstrom
et
al
et
al
oral
administr
bovin
antibodi
also
use
success
prophylaxi
bacteri
rotavir
diarrhea
man
treatment
human
rotaviru
infect
bogstedt
et
al
mitra
et
al
chicken
egg
yolk
antibodi
igi
protect
calv
bovin
rotaviru
kuroki
et
al
provis
passiv
immun
intranas
administr
antibodi
report
human
three
week
later
underw
surgic
instrument
random
iv
tpn
feed
n
chow
feed
n
follow
day
protocol
mice
sacrif
level
influenzaspecif
iga
nasal
secret
determin
elisa
normal
ngspecif
nasal
protein
chow
vs
iv
tpn
p
anova
influenzaspecif
iga
undetect
nonimmun
mice
c
influenzaspecif
serum
igg
titer
immun
mice
n
underw
instrument
random
iv
tpn
feed
n
chow
feed
n
follow
day
protocol
mice
sacrif
serum
igg
antiinfluenza
titer
nasal
viral
shed
determin
antibodi
titer
serum
dilut
elisa
absorb
read
greater
igg
titer
compar
chowf
tpnfed
immun
mice
tpnfed
mice
shed
viru
nasal
secret
none
chowf
mice
passiv
protect
immun
mice
fed
mous
chow
ivtpn
follow
day
respect
protocol
ivtpn
mice
divid
two
group
nonimmun
control
n
chowf
immun
mice
n
one
ivtpn
group
tpnnm
n
receiv
ascit
fluid
contain
mopc
recogn
influenza
piga
monoclon
ab
iv
second
ivtpn
group
tpnpiga
n
receiv
ascit
fluid
contain
piga
antiinfluenza
monoclon
ab
four
hour
later
mice
challeng
influenza
viru
hour
mice
euthan
nasal
secret
assay
viral
shed
nonparametr
statist
analysi
nonimmun
vs
tpnnm
p
ns
immun
vs
tpnpiga
p
ns
nonimmun
vs
immun
chowf
p
nonimmun
vs
tpnpiga
p
panel
ac
modifi
renegar
et
al
panel
renegar
et
al
nonhuman
primat
model
human
gamma
globulin
administ
intranas
show
promis
challeng
experi
influenza
coxsacki
virus
fruchtman
et
al
buthala
et
al
iga
antibodi
igabulin
given
nasal
spray
swedish
ski
team
albertvil
winter
olymp
game
significantli
reduc
level
upper
respiratori
tract
infect
et
al
howev
igabulin
treatment
effect
frequenc
upper
respiratori
tract
symptom
elit
canoeist
studi
hard
moder
train
regimen
lindberg
berglund
igabulin
nosedrop
treatment
variabl
immunodefici
patient
chronic
nasopharyng
carrier
nonencapsul
haemophilu
influenza
elimin
carrier
state
patient
allevi
cough
lindberg
et
al
heikkinen
et
al
treat
children
age
year
intranas
iga
placebo
found
reduct
rhiniti
igatr
group
thu
intranas
instil
antibodi
feasibl
may
prove
effect
manag
immunosuppress
patient
intranas
administr
specif
antibodi
may
prove
even
excit
weltzin
et
al
treat
rhesu
monkey
nose
drop
contain
mous
monoclon
iga
antibodi
respiratori
syncyti
viru
rsv
treat
monkey
reduc
viral
shed
nose
throat
lung
develop
neutral
serum
antibodi
rsv
even
absenc
detect
viral
replic
rsv
major
caus
lower
respiratori
tract
diseas
infant
young
children
produc
sever
diseas
children
underli
condit
heart
lung
result
suggest
prophylact
administr
monoclon
antibodi
nose
drop
could
provid
effect
protect
rsv
infect
atrisk
human
infant
